AllAnalyst Report
Morningstar•May 04, 2021
Morningstar•May 04, 2021Zimmer Biomet Holdings, Inc.: Zimmer Biomet Gains Steam in First Quarter; Raising Our Fair Value Estimate
Summary
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 60% of total revenue is derived from sales of large
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeActions
Download Full ReportRelated Reports
- Analyst Report: Fortive CorporationApr 24, 2024 •
FTV
- EW: Lowering target price to $92.00Apr 24, 2024 •
EW
- RMD: Lowering target price to $193.00Apr 24, 2024 •
RMD
- ALLE: What does Argus have to say about ALLE?Apr 24, 2024 •
ALLE
- UHS: Raising target price to $198.00Apr 24, 2024 •
UHS
Analyst Profile
Debbie Wang
Senior Equity AnalystDebbie Wang is a senior equity analyst for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. She covers the medical-device industry. Previously, she was an associate director of equity analysis for Morningstar, leading the healthcare team.Before joining Morningstar in 2002, Wang was a vice president and senior brand strategist for Leo Burnett. During her tenure at Leo Burnett, she led brand strategy on a variety of accounts, including Allstate, Amoco, McDonald/s, Heinz, Smucker’s, Pepto-Bismol, and Celebrex.Wang holds a bachelor’s degree in anthropology from Colgate University and a master’s degree in business administration from the University of Chicago Booth School of Business.